Xintela extends clinical study with XSTEM on knee osteoarthritis patients
Xintela has implemented a change to the clinical study protocol where the follow-up time for the patients at the highest dose level has been extended by 6 months to obtain additional efficacy data for XSTEM® 24 months after dosing. An interim analysis of study data up to 18 months post dosing for all dose levels […]
Xintelling, No. 3 2024
Read Xintela’s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]
Xintela AB Interim Report January – March 2024
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2024 for the groupIncome amounted to TSEK 299 (0).Loss before tax totalled TSEK 11,372 (loss: 15,843).Loss per share was SEK 0.02 (loss: 0.05). First quarter 2024 for the parent companyIncome amounted to TSEK 299 (0).Loss before […]
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Xintela and EQGen Biomedical Inc. have signed a non-binding term sheet for a license agreement where EQGen gets global rights to Xintela’s equine stem cell product EQSTEM®. Xintela and EQGen Biomedical, a newly formed US company, will collaborate on clinical development and commercialization of EQSTEM, initially in USA for the treatment of joint diseases in […]
Xintela AB publishes Annual Report 2023
Xintela AB (publ) announces that the company’s annual report for 2023 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]
Xintelling, No. 2 2024
Read Xintela’s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]
Xintela AB Year-end Report 2023
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. Fourth quarter 2023 for the groupIncome amounted to TSEK 78 (0).Loss before tax totalled TSEK 12,175 (loss: 23,384).Loss per share was SEK 0.03 (loss: 0.09). The year 2023 for the groupIncome amounted to TSEK 78 (0).Loss before and […]
Xintela appoints Lucienne Vonk as Chief Scientific Officer
Xintela announces that Lucienne Vonk, previously Director Musculoskeletal Diseases at Xintela, has been appointed Chief Scientific Officer. She takes over the role from the CEO Evy Lundgren-Åkerlund. “Lucienne Vonk joined Xintela about 1,5 years ago and has already made a great contribution to the development of our stem cell product XSTEM. Lucienne has extensive experience […]
Xintela newsletter, No. 1 2024
Read Xintela’s newsletter in English here. Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company’s cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain […]
First patient dosed in Xintela’s clinical study on difficult-to-heal leg ulcers
Xintela announces that the first patient has been dosed in the company’s clinical Phase I/IIa study with XSTEM® in patients with difficult-to-heal venous leg ulcers. XSTEM, which consists of allogeneic (donated) integrin α10β1-selected mesenchymal stem cells, is developed and manufactured by Xintela. Xintela’s ongoing Phase I/IIa clinical study in patients with difficult-to-heal venous leg ulcers […]
